Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cerus's Sloan Ratio for the quarter that ended in Jun. 2026 was -13.60%.
As of Jun. 2026, Cerus has a Sloan Ratio of -13.60%, indicating there is a warning stage of accrual build up.
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Cerus has a Sloan Ratio of -13.60%, indicating there is a warning stage of accrual build up.
Cerus Sloan Ratio % Related Terms
Cerus Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Cerus's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CU2 vs CTKB, TCMD, CBLL: Sloan Ratio % Comparison
For the Medical Devices subindustry, Cerus's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cerus's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cerus's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Cerus's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -0.016 (Sep. 2025 ) + -1.865 (Dec. 2025 ) + -1.419 (Mar. 2026 ) + -2.552 (Jun. 2026 ) = €-5.9 Mil.
Cerus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 1.642 (Sep. 2025 ) + 5.295 (Dec. 2025 ) + -2.637 (Mar. 2026 ) + -2.31 (Jun. 2026 ) = €2.0 Mil.
Cerus's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -2.138 (Sep. 2025 ) + -1.177 (Dec. 2025 ) + 8.529 (Mar. 2026 ) + 11.168 (Jun. 2026 ) = €16.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (STU:CU2) has a Sloan Ratio % of -13.60% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cerus and its competitors.
Is Cerus' Sloan Ratio % too high?
Cerus' current Sloan Ratio % is -13.60%. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' Sloan Ratio % compare to CTKB and TCMD?
Cerus' Sloan Ratio % of -13.60% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cerus and its competitors. Cerus's current Sloan Ratio % is -13.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (STU:CU2) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €2.34 — trading 18.8% above its estimated fair value. The current Sloan Ratio % is -13.60%. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cerus (STU:CU2), the current Sloan Ratio % is -13.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (STU:CU2) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for STU:CU2:
Sloan Ratio %: -13.60%
GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for STU:CU2
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CU2 has been successfully added to your 
